Boston Scientific will buy privately held Asthmatx Inc. in a deal that could be worth more than $440 million, the medical device maker said.
Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS.
Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.
Bristol-Myers Squibb Company and AstraZeneca announced that a randomized, double blind Phase 3 clinical study demonstrated that the addition of dapagliflozin to existing glimepiride therapy produced significant reductions in HbA1c in adult patients with type 2 diabetes compared to glimepiride alone.
Harbor BioSciences, Inc. announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286).
The Food and Drug Administration is reviewing data suggesting a possible link between the widely used diabetes medication Actos and bladder cancer.
Researchers say they've found a possible new treatment for adults with hard-to-control asthma. Their discovery, however, came at a price.
Operating as a division of Worldwide Clinical Trials over the past three years, CEDRA Corporation announces its new company name, Worldwide Clinical Trials Drug Development Solutions.
Like other sectors of the drug discovery and development process, drug formulation and drug delivery research has been challenged with finding effective and economical routes to bringing a drug to its target.
SafeScint 1:1 from LabLogic Systems is a scintillation cocktail for discrete sample counting with a biodegradable formulation and outstanding counting efficiency with a high sample uptake capacity that saves on both consumption and disposal.
Pall Corporation announced the introduction of the GeneDisc Rapid Microbiology System for advanced microbial quality monitoring. This system represents Pall’s latest quality assurance innovation for the pharmaceutical manufacturing industry.
Cellular Dynamics International (CDI) announced their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.
The head of the Johnson & Johnson division responsible for most of the company's 11 product recalls announced her retirement, shortly after a congressional committee probing the recalls invited her to a second hearing on the case.
After review of the program's full development strategy, GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications and will stop further development work on the intravenous route of administration in autoimmune disease.
Scripps Research Institute has been awarded grant by the National Institutes of Health to help develop the next generation of DNA sequencing technologies, which could enable biomedical researchers and health care workers to routinely sequence a person’s DNA.